6-K 1 d920566d6k.htm 6-K 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of May 2015

Commission File Number: 001-36697

 

 

DBV TECHNOLOGIES S.A.

(Translation of registrant’s name into English)

 

 

Green Square-Bâtiment D

80/84 rue des Meuniers

92220 Bagneux France

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  x            Form 40-F  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ¨

 

 

 

EXHIBITS

 

Exhibit

   

Description

99.1    DBV Technologies to Present at Upcoming Investor Conferences

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

DBV TECHNOLOGIES S.A.
Date: May 5, 2015 By:

 /s/ David Schilansky

David Schilansky
Chief Operating Officer

Exhibit 99.1

 

LOGO

Press Release

Bagneux, France, May 5, 2015

DBV Technologies to Present at Upcoming Investor Conferences

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced that members of its management team will present and host investor meetings at the following upcoming investor conferences:

 

  •   Bank of America Merrill Lynch 2015 Health Care Conference on Tuesday, May 12, 2015, at 8:40 am ET in Las Vegas, NV.

 

  •   2015 UBS Global Healthcare Conference on Wednesday, May 20, 2015 at 12:00 pm ET in New York, NY.

A live audio webcast of these presentations will be available on the Investor Relations section of the company’s website, http://www.dbv-technologies.com/en/investor-relations. A replay of the presentations will be available on DBV’s website within 48 hours after the event.

About DBV Technologies

DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies – a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus considerably lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration.

DBV Technologies shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com.

DBV Technologies Contacts

 

Nathalie Donne Susanna Mesa

Director, Corporate Communication & Business Development

Tél. : +33(0)1 55 42 78 72

[email protected]

VP Finance, US Investor Relations & Strategy

Tél. : +1 917-346-3447

[email protected]

DBV Technologies Media Contacts

Marion Janic

Rooney & Associates

Tél. : +1-212-223-4017

[email protected]